

Glaxo brief : growing clinical evidence strengthens the case for Ceporin : broad-spectrum, bactericidal antibiotic.

Contributors

Glaxo Laboratories

Publication/Creation

[between 1965 and 1975?]

Persistent URL

<https://wellcomecollection.org/works/k4xzkkvp>

License and attribution

Conditions of use: it is possible this item is protected by copyright and/or related rights. You are free to use this item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s).

**wellcome
collection**

Wellcome Collection
183 Euston Road
London NW1 2BE UK
T +44 (0)20 7611 8722
E library@wellcomecollection.org
<https://wellcomecollection.org>

**GLAXO
BRIEF**

**Growing clinical evidence
strengthens the
case for Ceporin
broad-spectrum, bactericidal
antibiotic**

A recent analysis of the results from over 1,500 cases treated with Ceporin (cephaloridine) has indicated high success rates in a wide variety of infections—including infections of the urinary and respiratory tracts, soft tissue infections, septicaemias and infections of the genital tract. The reports have been drawn from centres in many parts of the world. Many mention the rapid response obtained with Ceporin after other antibiotics had failed.

Reports on toxicity and side effects have confirmed the laboratory evidence that Ceporin has remarkably low toxicity—even when high doses are given for long periods. With dosage as high as 6 grams daily, there have been instances of hyaline and granular casts appearing in the urine—but without proteinuria or disturbance of renal function. Quite apart from these cases, there have been rare reports of disturbance of renal function associated with high dosage, or where kidney dysfunction already existed. Thus, in renal failure, renal function should be monitored and dosage may need to be adjusted accordingly. Nevertheless, in urinary tract infection Ceporin's bactericidal action has proven particularly valuable.

Occasional reports have mentioned the occurrence of skin rashes during treatment but the antibiotic is usually well tolerated by patients hypersensitive to penicillin. Symptoms of cerebral irritation have been observed after intrathecal doses of 100 mg and there have also been rare reports of mild and transient neutropenia, and of a temporary rise in S.G.O.T. This evidence of Ceporin's safety and broad-spectrum effectiveness makes a strong case for its use in place of long courses of more toxic drugs or combinations of antibiotics. As it is effective against penicillin-resistant staphylococci—and usually tolerated well by patients allergic to penicillin—it can also be used to bring a quick clinical response in many serious infections where penicillin might prove ineffective or dangerous.

Presentation

1 x 250 mg vial
5 x 250 mg vials
1 x 500 mg vial
5 x 500 mg vials
1 x 1 gram vial
5 x 1 gram vials

Net Hospital Price

8/4
39/-
15/8
75/-
30/-
146/4

Quantity rates are available on request.

Ceporin is a Glaxo trade mark